BiotechTube
KaloCyte

KaloCyte

St. Louis, United States· Est.
kalocyte.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.5M

Overview

KaloCyte is pioneering a first-in-class, shelf-stable artificial red blood cell substitute called ErythroMer™, targeting the critical gap in transfusion medicine for pre-hospital and austere environments. Founded by experts in physiology, trauma care, and nanotechnology, the company has secured over $27 million in non-dilutive government grants and investor funding to advance its platform. As a BLUE KNIGHT™ company partnered with Johnson & Johnson Innovation and BARDA, KaloCyte is positioned to advance ErythroMer towards Investigational New Drug (IND)-enabling studies and first-in-human trials.

Trauma & Critical CareHematology

Technology Platform

ErythroMer™ platform: A bio-inspired, nano-encapsulated human hemoglobin designed to mimic natural red blood cell physiology. The nanoparticles are freeze-dried for long-term, ambient-temperature storage and reconstitution.

Funding History

2
Total raised:$3.5M
Seed$3M
Grant$500K

Opportunities

The massive, unmet need for a shelf-stable, universally compatible oxygen carrier in pre-hospital trauma, military medicine, and resource-limited settings represents a multi-billion dollar market.
Strategic government partnerships (DARPA, DoD, BARDA) provide non-dilutive funding and a potential fast-track procurement pathway for national security and emergency preparedness use.

Risk Factors

High clinical development risk inherent to the historically challenging blood substitute field, with previous failures due to safety issues.
Significant regulatory hurdles for a first-in-class biologic.
Manufacturing scale-up of a complex nanoparticle product presents technical and cost challenges.

Competitive Landscape

The field of artificial blood substitutes is sparse after decades of high-profile failures. KaloCyte's primary competition remains donated human blood, though its product targets scenarios where blood is not an option. Other developers are exploring hemoglobin-based or perfluorocarbon-based approaches, but ErythroMer's nano-encapsulation and dried formulation appear to be key differentiating features.

More companies in United States →